{"id":"toripalimab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Toripalimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells and immune cells. This blockade reverses T cell exhaustion and restores anti-tumor immune responses. It is a humanized IgG4 monoclonal antibody designed to enhance endogenous anti-tumor immunity.","oneSentence":"Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:31.363Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma"},{"name":"Non-small cell lung cancer"},{"name":"Nasopharyngeal carcinoma"},{"name":"Esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07480733","phase":"PHASE2","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2026-04-02","conditions":"Advanced Malignant Solid Tumors","enrollment":480},{"nctId":"NCT05707910","phase":"PHASE1","title":"Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2023-02-08","conditions":"Malignant Tumor","enrollment":6},{"nctId":"NCT07445295","phase":"PHASE3","title":"Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2026-03-31","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":558},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT07281976","phase":"PHASE1, PHASE2","title":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-01-27","conditions":"Triple Negative Breast Cancer","enrollment":220},{"nctId":"NCT07392736","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2021-10-26","conditions":"Solid Tumor","enrollment":228},{"nctId":"NCT05518045","phase":"PHASE1, PHASE2","title":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2022-08-26","conditions":"Advanced Solid Tumor","enrollment":392},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT07362186","phase":"PHASE3","title":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2026-04-03","conditions":"Locally Advanced or Metastatic GC and GCJ Adenocarcinoma","enrollment":400},{"nctId":"NCT07353723","phase":"PHASE2","title":"Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-11-15","conditions":"Head & Neck Cancer","enrollment":10},{"nctId":"NCT07342322","phase":"PHASE2","title":"A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-02-01","conditions":"Soft Tissue Sarcoma (STS)","enrollment":25},{"nctId":"NCT04284488","phase":"PHASE1, PHASE2","title":"Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors","status":"TERMINATED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-04-10","conditions":"Advanced Solid Tumor","enrollment":40},{"nctId":"NCT06283134","phase":"PHASE1","title":"A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-03","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT07314723","phase":"PHASE2","title":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-08-01","conditions":"Urothelial Carcinoma","enrollment":90},{"nctId":"NCT07309276","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-12-30","conditions":"Advanced Lung Cancer","enrollment":864},{"nctId":"NCT07308379","phase":"","title":"Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02","conditions":"SCLC, Extensive Stage, Toripalimab","enrollment":1200},{"nctId":"NCT06380309","phase":"EARLY_PHASE1","title":"A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-05-06","conditions":"Advanced Malignant Solid Tumor of Digestive System","enrollment":89},{"nctId":"NCT07111832","phase":"PHASE3","title":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-20","conditions":"PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer","enrollment":400},{"nctId":"NCT07099430","phase":"PHASE1, PHASE2","title":"A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-09-05","conditions":"Advanced Melanoma","enrollment":200},{"nctId":"NCT05427396","phase":"PHASE1","title":"A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-07-28","conditions":"Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer","enrollment":31},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT07245901","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-12-05","conditions":"Solid Tumor","enrollment":60},{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06462222","phase":"PHASE1, PHASE2","title":"Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2024-06-30","conditions":"Leptomeningeal Metastasis","enrollment":45},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT06730932","phase":"PHASE2","title":"A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-10-30","conditions":"Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy","enrollment":31},{"nctId":"NCT06682780","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","status":"RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2025-09-17","conditions":"Advanced Solid Tumor","enrollment":320},{"nctId":"NCT04640545","phase":"PHASE1","title":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma","status":"COMPLETED","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2020-05-12","conditions":"Advanced Melanoma","enrollment":79},{"nctId":"NCT07169994","phase":"PHASE1, PHASE2","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2025-09-02","conditions":"Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer","enrollment":414},{"nctId":"NCT03581786","phase":"PHASE3","title":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-10-18","conditions":"Recurrent or Metastatic NPC","enrollment":289},{"nctId":"NCT06088004","phase":"PHASE1, PHASE2","title":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2023-09-28","conditions":"Solid Tumor, Adult","enrollment":218},{"nctId":"NCT06371274","phase":"NA","title":"A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-10","conditions":"Triple-negative Breast Cancer","enrollment":29},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT03829969","phase":"PHASE3","title":"Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-01-31","conditions":"Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy","enrollment":514},{"nctId":"NCT07054086","phase":"","title":"Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT06228079","phase":"PHASE3","title":"Adjuvant vs Surgery Only in Early-stage Recurrent NPC","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-06-25","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":176},{"nctId":"NCT07004244","phase":"PHASE1","title":"Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-06-05","conditions":"Malignant Tumors","enrollment":20},{"nctId":"NCT04991506","phase":"PHASE1","title":"A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Elpiscience Biopharma, Ltd.","startDate":"2021-10-15","conditions":"Solid Tumor, Neoplasms, Malignant Tumor","enrollment":30},{"nctId":"NCT02836795","phase":"PHASE1","title":"Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2016-04","conditions":"Melanoma, Urological Cancer","enrollment":35},{"nctId":"NCT06235203","phase":"PHASE3","title":"Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-07-09","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":154},{"nctId":"NCT05102006","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors","status":"COMPLETED","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2021-11-30","conditions":"Advanced Malignant Tumors","enrollment":80},{"nctId":"NCT04322006","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of TJ004309 for Advanced Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2020-05-09","conditions":"Advanced Solid Tumor","enrollment":376},{"nctId":"NCT05830539","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-03-10","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":68},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT06919848","phase":"PHASE2","title":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-05-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":74},{"nctId":"NCT06903871","phase":"PHASE2","title":"Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-04-01","conditions":"Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III","enrollment":190},{"nctId":"NCT06888531","phase":"PHASE2","title":"Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-03-08","conditions":"Esophageal Malignant Neoplasm Primary","enrollment":30},{"nctId":"NCT06889649","phase":"PHASE2","title":"SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-01-01","conditions":"Radiation Therapy, Targeted Therapy, Immunotherapy","enrollment":30},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT06873854","phase":"PHASE2","title":"A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours","status":"NOT_YET_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2025-03-26","conditions":"Advanced Solid Tumor","enrollment":84},{"nctId":"NCT06571422","phase":"PHASE1","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-10-23","conditions":"Advanced Malignant Solid Tumors","enrollment":93},{"nctId":"NCT05000684","phase":"PHASE1, PHASE2","title":"Study of JS004 Combined With Toripalimab for Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-08-27","conditions":"Advanced Lung Cancer","enrollment":67},{"nctId":"NCT06671262","phase":"PHASE2","title":"Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-12-26","conditions":"Breast Adenocarcinoma","enrollment":74},{"nctId":"NCT05021328","phase":"PHASE1","title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","status":"COMPLETED","sponsor":"Hubei Cancer Hospital","startDate":"2021-10-01","conditions":"NSCLC","enrollment":13},{"nctId":"NCT05033392","phase":"PHASE2","title":"PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Wan He","startDate":"2021-09-14","conditions":"Stomach Neoplasms","enrollment":62},{"nctId":"NCT06038396","phase":"PHASE1, PHASE2","title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-03","conditions":"Advanced Solid Tumor","enrollment":48},{"nctId":"NCT04012606","phase":"PHASE3","title":"Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-07-23","conditions":"Small Cell Lung Cancer","enrollment":442},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06472713","phase":"PHASE2","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2024-07-20","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT05031494","phase":"PHASE2","title":"A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers","status":"COMPLETED","sponsor":"Eucure (Beijing) Biopharma Co., Ltd","startDate":"2021-12-08","conditions":"Melanoma, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT06732258","phase":"PHASE1","title":"Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-01-10","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":12},{"nctId":"NCT05615974","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2023-01-11","conditions":"Malignant Tumors","enrollment":139},{"nctId":"NCT06721286","phase":"PHASE2","title":"Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-11-12","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":70},{"nctId":"NCT06717464","phase":"PHASE2","title":"Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-11-12","conditions":"Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma","enrollment":110},{"nctId":"NCT06709274","phase":"NA","title":"Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2024-11","conditions":"Non-Small Cell Lung Cancer","enrollment":342},{"nctId":"NCT06705127","phase":"PHASE2","title":"Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-01","conditions":"HR-positive,HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT06410703","phase":"PHASE1, PHASE2","title":"CAN1012 Combined With PD-1 in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Canwell Biotech Limited","startDate":"2024-06-27","conditions":"Advanced Solid Tumor","enrollment":71},{"nctId":"NCT06666153","phase":"PHASE1","title":"Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-10","conditions":"CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs","enrollment":27},{"nctId":"NCT06592326","phase":"PHASE3","title":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-08-22","conditions":"Urothelial Carcinoma","enrollment":460},{"nctId":"NCT06079112","phase":"PHASE1, PHASE2","title":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2023-09-27","conditions":"Advanced Urothelial Carcinoma","enrollment":100},{"nctId":"NCT06561763","phase":"PHASE3","title":"TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-20","conditions":"High Risk Locally Advanced Nasopharyngeal Carcinoma","enrollment":416},{"nctId":"NCT06378177","phase":"PHASE2","title":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"RECRUITING","sponsor":"Lyvgen Biopharma Holdings Limited","startDate":"2024-06-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":64},{"nctId":"NCT06359275","phase":"PHASE2","title":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-01","conditions":"Pancreatic Cancer","enrollment":81},{"nctId":"NCT06095583","phase":"PHASE3","title":"Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-11-15","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":756},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT05955105","phase":"PHASE1, PHASE2","title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Innolake Biopharm","startDate":"2023-07-25","conditions":"Head and Neck Cancer, Cervical Cancer, Endometrial Cancer","enrollment":200},{"nctId":"NCT05579275","phase":"EARLY_PHASE1","title":"Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-02-06","conditions":"Malignant Solid Tumors","enrollment":24},{"nctId":"NCT06370754","phase":"PHASE1, PHASE2","title":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-04-30","conditions":"Pancreatic Cancer","enrollment":117},{"nctId":"NCT05148533","phase":"PHASE1, PHASE2","title":"A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor","status":"TERMINATED","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2021-12-30","conditions":"Advanced Solid Tumor","enrollment":7},{"nctId":"NCT06227117","phase":"PHASE2","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-07-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT06187597","phase":"PHASE2","title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":140},{"nctId":"NCT04605185","phase":"PHASE1","title":"Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-01-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT06283121","phase":"PHASE2","title":"A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2024-04-02","conditions":"Gastric Cancer, Metastatic","enrollment":30},{"nctId":"NCT06283303","phase":"PHASE1","title":"A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2024-04-02","conditions":"Colorectal Cancer Metastatic","enrollment":8},{"nctId":"NCT04137900","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"TopAlliance Biosciences","startDate":"2019-10-30","conditions":"Advanced Unresectable Solid Tumor, Metastatic Solid Tumor","enrollment":499},{"nctId":"NCT06221774","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-02-01","conditions":"Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer","enrollment":42},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT05015621","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2021-09-18","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":194},{"nctId":"NCT03867370","phase":"PHASE1, PHASE2","title":"Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-04-26","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05580445","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2022-08-11","conditions":"Advanced Pancreatic Cancer","enrollment":114},{"nctId":"NCT04473716","phase":"PHASE1","title":"Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-07-30","conditions":"Oral Cancer, Induction Chemotherapy, Programmed Cell Death 1 Inhibitor","enrollment":20},{"nctId":"NCT06078670","phase":"PHASE1, PHASE2","title":"PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-10-10","conditions":"Advanced Solid Tumor","enrollment":96},{"nctId":"NCT04737122","phase":"PHASE1","title":"Study of LM-061 in Subjects in Advanced Tumors","status":"TERMINATED","sponsor":"LaNova Medicines Limited","startDate":"2021-05-06","conditions":"Advanced Tumours","enrollment":18},{"nctId":"NCT04357756","phase":"PHASE1","title":"A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eucure (Beijing) Biopharma Co., Ltd","startDate":"2020-04-21","conditions":"Advanced Solid Tumor","enrollment":29},{"nctId":"NCT05979740","phase":"PHASE2","title":"RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-08-01","conditions":"Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy","enrollment":6},{"nctId":"NCT06009705","phase":"","title":"Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2022-10-01","conditions":"Esophageal Carcinoma","enrollment":56},{"nctId":"NCT03513666","phase":"PHASE2","title":"A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-04-09","conditions":"NSCLC","enrollment":40},{"nctId":"NCT05996484","phase":"PHASE2","title":"Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-09","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JS001","PD-1 inhibitor","Toripalimab","EBV-DNA positive"],"phase":"phase_3","status":"active","brandName":"Toripalimab injection","genericName":"Toripalimab injection","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Melanoma, Non-small cell lung cancer, Nasopharyngeal carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}